View Past PerformanceThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsTyme Technologies 대차대조표 건전성재무 건전성 기준 점검 6/6핵심 정보0%부채/자본 비율US$0부채이자보상배율n/a현금US$77.11m자본US$74.14m총부채US$6.02m총자산US$80.16m최근 재무 건전성 업데이트분석 기사 • Aug 05We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...분석 기사 • Mar 19We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Nov 19Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Jul 19We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Mar 26Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...분석 기사 • Dec 09Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...모든 업데이트 보기Recent updatesSeeking Alpha • Sep 15Syros, Tyme Technologies jump more than 20% after hours as shareholders approve mergerShareholders of Syros Pharmaceuticals (NASDAQ:SYRS) and Tyme Technologies (NASDAQ:TYME) on Thursday voted in favor of the merger between the two biotech companies. SYRS and TYME stock gained more than 20% each in aftermarket trading - SYRS +22% and TYME +24%. Both SYRS and TYME held special stockholder meetings to vote on the merger, the companies said in a statement. SYRS shareholders also voted in favor of the company's concurrent private investment in public equity (PIPE) financing. The closing of the merger and the PIPE financing are anticipated to take place on or around Sept. 16. Post the closing of the merger, the combined company will trade on the Nasdaq under the ticker symbol "SYRS". SYRS also announced a 1-for-10 reverse stock split, with the stock to begin trading on a split-adjusted basis on the Nasdaq on Sept. 19.분석 기사 • Aug 05We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Jul 05TYME stock surges on merger agreement and Syros PharmaceuticalsDevelopment stage biotech firms Syros Pharmaceuticals (SYRS) and Tyme Technologies (NASDAQ:TYME) announced on Tuesday that the companies entered into a definitive merger agreement following which Syros (SYRS) will acquire Tyme (TYME). Tyme (TYME) has added ~23% in the pre-market so far while Syros (SYRS) is trading ~6% higher. Per the terms, Syros (SYRS) will issue ~74.3M shares of its common stock to TYME investors and TYME stockholders are entitled to nearly 0.4312 shares of Syros (SYRS) common stock for each TYME stock they hold. The deal is worth about $60M net of wind-down and transaction expenses. Following the merger, the combined entity will be led by Syros’ existing management team and trade on Nasdaq under the ticker symbol “SYRS.” Separately, Syros (SYRS) disclosed an oversubscribed $130M financing of private investment in public equity (PIPE) to purchase a total of up to 138.1M additional shares of common stock at $0.94 apiece. In addition, Syros (SYRS) also announced an amendment to its senior secured loan facility with Oxford Finance LLC. The terms include one year extension to the interest-only payment period and maturity dates subject to conditions revising them to March 1, 2024, and February 1, 2026, respectively. The transactions are expected to close in H2 2022.Seeking Alpha • May 26Tyme Technologies: Net-Net Biopharma Exploring Strategic AlternativesTyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives. Board seems to be leaning towards a sale of the company.Recent Insider Transactions Derivative • May 04Co-Founder & Director notifies of intention to sell stockSteven Hoffman intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 27th of April. If the sale is conducted around the recent share price of US$0.31, it would amount to US$561k. Since June 2021, Steven's direct individual holding has decreased from 23.99m shares to 20.65m. Company insiders have collectively sold US$801k more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • May 02Co-Founder & Director notifies of intention to sell stockSteven Hoffman intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 27th of April. If the sale is conducted around the recent share price of US$0.31, it would amount to US$561k. Since June 2021, Steven's direct individual holding has decreased from 23.99m shares to 20.65m. Company insiders have collectively sold US$800k more than they bought, via options and on-market transactions in the last 12 months.Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. CEO & Director Richie Cunningham was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Mar 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. CEO & Director Richie Cunningham was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.분석 기사 • Mar 19We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Recent Insider Transactions Derivative • Feb 03Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 25th of January. If the sale is conducted around the recent share price of US$0.50, it would amount to US$854k. Since March 2021, Steven's direct individual holding has decreased from 24.49m shares to 21.59m. Company insiders have collectively sold US$1.2m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Feb 01Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 25th of January. If the sale is conducted around the recent share price of US$0.50, it would amount to US$854k. Since March 2021, Steven's direct individual holding has decreased from 24.49m shares to 21.59m. Company insiders have collectively sold US$1.2m more than they bought, via options and on-market transactions in the last 12 months.Seeking Alpha • Dec 07Tyme Technologies Offers Incredible Risk-RewardTyme Technologies recently reported their Q2 earnings that revealed the company only burned roughly $5M in cash with about $97M left in the bank. The small-cap sell-off has pushed the share price to fresh 52-week lows. I believe TYME has an incredible risk-reward at these prices. I review some of the company’s updates and point out a few bullish highlights for investors. In addition, I discuss some of my lingering downside risks for TYME. I update investors on my strategy for managing my TYME position and how I intend to take advantage of the sell-off.분석 기사 • Nov 19Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Recent Insider Transactions Derivative • Nov 01Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 1m shares in the next 90 days after lodging an Intent To Sell Form on the 26th of October. If the sale is conducted around the recent share price of US$0.97, it would amount to US$1.4m. Since December 2020, Steven's direct individual holding has decreased from 25.04m shares to 22.52m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Sep 25Independent Director recently bought US$52k worth of stockOn the 22nd of September, David Carberry bought around 50k shares on-market at roughly US$1.03 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold US$2.0m more in shares than they bought in the last 12 months.Seeking Alpha • Aug 27Tyme Technologies: The Market Missed The Bullish MemoTyme Technologies recently made some big moves following a strategic review. I believe the market has missed the bullish memo about these changes. I review some of these significant changes and provide a bullish memo for investors. In addition, I discuss how these changes have addressed my downside concerns. The recent sell-off provided me with an opportunity to load up near the 52-week lows. I update investors on my strategy for managing my TYME position.Recent Insider Transactions Derivative • Jul 29Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 1m shares in the next 90 days after lodging an Intent To Sell Form on the 20th of July. If the sale is conducted around the recent share price of US$1.05, it would amount to US$1.5m. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 23.84m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Jul 27Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 1m shares in the next 90 days after lodging an Intent To Sell Form on the 20th of July. If the sale is conducted around the recent share price of US$1.05, it would amount to US$1.5m. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 23.84m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Jul 24Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 1m shares in the next 90 days after lodging an Intent To Sell Form on the 20th of July. If the sale is conducted around the recent share price of US$1.05, it would amount to US$1.5m. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 23.84m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.분석 기사 • Jul 19We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...Recent Insider Transactions Derivative • May 03Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 414k shares in the next 90 days after lodging an Intent To Sell Form on the 27th of April. If the sale is conducted around the recent share price of US$1.60, it would amount to US$662k. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 24.32m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.Price Target Changed • Apr 03Price target increased to US$9.44Up from US$8.50, the current price target is provided by 1 analyst. New target price is 405% above last closing price of US$1.87. Stock is up 87% over the past year.Executive Departure • Apr 02Chief Medical Officer has left the companyOn the 31st of March, Giuseppe Del Priore's tenure in the role of Chief Medical Officer ended. We don't have any record of a personal shareholding under Giuseppe's name. A total of 2 executives have left over the last 12 months.분석 기사 • Mar 26Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Recent Insider Transactions • Feb 21Insider recently sold US$55k worth of stockOn the 16th of February, Michael Demurjian sold around 20k shares on-market at roughly US$2.77 per share. In the last 3 months, there was an even bigger sale from another insider worth US$613k. Insiders have been net sellers, collectively disposing of US$1.8m more than they bought in the last 12 months.분석 기사 • Feb 19Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?Investors may wish to note that an insider of Tyme Technologies, Inc. , Michael Demurjian, recently netted US$55k from...Recent Insider Transactions • Feb 19Insider recently sold US$55k worth of stockOn the 16th of February, Michael Demurjian sold around 20k shares on-market at roughly US$2.77 per share. In the last 3 months, there was an even bigger sale from another insider worth US$613k. Insiders have been net sellers, collectively disposing of US$1.8m more than they bought in the last 12 months.Is New 90 Day High Low • Feb 04New 90-day high: US$3.53The company is up 265% from its price of US$0.97 on 05 November 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 18% over the same period.분석 기사 • Feb 02Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?A look at the shareholders of Tyme Technologies, Inc. ( NASDAQ:TYME ) can tell us which group is most powerful...Recent Insider Transactions Derivative • Jan 24Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell roughly 519.00k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of January. If the sale is conducted around the recent share price of US$1.88, it would amount to US$976k. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 24.93m. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months.Is New 90 Day High Low • Jan 05New 90-day high: US$1.34The company is up 36% from its price of US$0.98 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Recent Insider Transactions • Dec 16Co-Founder recently sold US$613k worth of stockOn the 14th of December, Steven Hoffman sold around 500k shares on-market at roughly US$1.23 per share. This was the largest sale by an insider in the last 3 months. This was Steven's only on-market trade for the last 12 months.Recent Insider Transactions Derivative • Dec 16Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell roughly 500.00k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of December. If the sale is conducted around the recent share price of US$1.26, it would amount to US$630k. Since December 2019, Steven's direct individual holding has decreased from 26.49m shares to 25.65m. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months.분석 기사 • Dec 16Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?We wouldn't blame Tyme Technologies, Inc. ( NASDAQ:TYME ) shareholders if they were a little worried about the fact...분석 기사 • Dec 09Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...Is New 90 Day High Low • Dec 01New 90-day high: US$1.05The company is up 7.0% from its price of US$0.99 on 01 September 2020. The American market is also up 7.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 27New 90-day low: US$0.92The company is down 23% from its price of US$1.20 on 29 July 2020. The American market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Recent Insider Transactions Derivative • Oct 24Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell roughly 543.00k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of October. If the sale is conducted around the recent share price of US$1.00, it would amount to US$543k. For the year to March 2020, Steven's total compensation was 61% salary and 39% non-salary. Since December 2019, Steven's direct individual holding has decreased from 26.49m shares to 25.95m. Company insiders have collectively sold US$1.1m more than they bought, via options and on-market transactions in the last 12 months.재무 상태 분석단기부채: TYME 의 단기 자산 ( $79.0M )이 단기 부채( $5.6M ).장기 부채: TYME의 단기 자산($79.0M)이 장기 부채($400.9K)를 초과합니다.부채/자본 비율 추이 및 분석부채 수준: TYME 부채가 없습니다.부채 감소: TYME는 5년 전에 부채가 없었습니다.대차대조표현금 보유 기간 분석과거에 평균적으로 손실을 기록해 온 기업의 경우, 최소 1년 이상의 현금 보유 기간이 있는지 평가합니다.안정적인 현금 활주로: TYME 현재 무료 현금 흐름을 기준으로 3년 이상 충분한 현금 활주로를 보유하고 있습니다.예측 현금 활주로: 무료 현금 흐름이 매년 18.3 %의 역사적 비율로 계속 감소한다면 TYME ) 3년 이상 충분한 현금 활주로를 보유하고 있습니다.건전한 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 건실한 기업.View Dividend기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2022/09/16 14:43종가2022/09/16 00:00수익2022/06/30연간 수익2022/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Tyme Technologies, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Arlinda LeeCanaccord GenuityJoshua SchimmerEvercore ISISwayampakula RamakanthH.C. Wainwright & Co.
분석 기사 • Aug 05We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
분석 기사 • Mar 19We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Nov 19Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Jul 19We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Mar 26Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
분석 기사 • Dec 09Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Sep 15Syros, Tyme Technologies jump more than 20% after hours as shareholders approve mergerShareholders of Syros Pharmaceuticals (NASDAQ:SYRS) and Tyme Technologies (NASDAQ:TYME) on Thursday voted in favor of the merger between the two biotech companies. SYRS and TYME stock gained more than 20% each in aftermarket trading - SYRS +22% and TYME +24%. Both SYRS and TYME held special stockholder meetings to vote on the merger, the companies said in a statement. SYRS shareholders also voted in favor of the company's concurrent private investment in public equity (PIPE) financing. The closing of the merger and the PIPE financing are anticipated to take place on or around Sept. 16. Post the closing of the merger, the combined company will trade on the Nasdaq under the ticker symbol "SYRS". SYRS also announced a 1-for-10 reverse stock split, with the stock to begin trading on a split-adjusted basis on the Nasdaq on Sept. 19.
분석 기사 • Aug 05We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Seeking Alpha • Jul 05TYME stock surges on merger agreement and Syros PharmaceuticalsDevelopment stage biotech firms Syros Pharmaceuticals (SYRS) and Tyme Technologies (NASDAQ:TYME) announced on Tuesday that the companies entered into a definitive merger agreement following which Syros (SYRS) will acquire Tyme (TYME). Tyme (TYME) has added ~23% in the pre-market so far while Syros (SYRS) is trading ~6% higher. Per the terms, Syros (SYRS) will issue ~74.3M shares of its common stock to TYME investors and TYME stockholders are entitled to nearly 0.4312 shares of Syros (SYRS) common stock for each TYME stock they hold. The deal is worth about $60M net of wind-down and transaction expenses. Following the merger, the combined entity will be led by Syros’ existing management team and trade on Nasdaq under the ticker symbol “SYRS.” Separately, Syros (SYRS) disclosed an oversubscribed $130M financing of private investment in public equity (PIPE) to purchase a total of up to 138.1M additional shares of common stock at $0.94 apiece. In addition, Syros (SYRS) also announced an amendment to its senior secured loan facility with Oxford Finance LLC. The terms include one year extension to the interest-only payment period and maturity dates subject to conditions revising them to March 1, 2024, and February 1, 2026, respectively. The transactions are expected to close in H2 2022.
Seeking Alpha • May 26Tyme Technologies: Net-Net Biopharma Exploring Strategic AlternativesTyme Technologies is a clinical-stage biopharma company trading at a large discount to net cash + marketable securities. After the company discontinued the development of its primary compound, they have announced exploration of strategic alternatives. Board seems to be leaning towards a sale of the company.
Recent Insider Transactions Derivative • May 04Co-Founder & Director notifies of intention to sell stockSteven Hoffman intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 27th of April. If the sale is conducted around the recent share price of US$0.31, it would amount to US$561k. Since June 2021, Steven's direct individual holding has decreased from 23.99m shares to 20.65m. Company insiders have collectively sold US$801k more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • May 02Co-Founder & Director notifies of intention to sell stockSteven Hoffman intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 27th of April. If the sale is conducted around the recent share price of US$0.31, it would amount to US$561k. Since June 2021, Steven's direct individual holding has decreased from 23.99m shares to 20.65m. Company insiders have collectively sold US$800k more than they bought, via options and on-market transactions in the last 12 months.
Board Change • Apr 27Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. CEO & Director Richie Cunningham was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Mar 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. CEO & Director Richie Cunningham was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
분석 기사 • Mar 19We Think Tyme Technologies (NASDAQ:TYME) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Recent Insider Transactions Derivative • Feb 03Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 25th of January. If the sale is conducted around the recent share price of US$0.50, it would amount to US$854k. Since March 2021, Steven's direct individual holding has decreased from 24.49m shares to 21.59m. Company insiders have collectively sold US$1.2m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Feb 01Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 2m shares in the next 90 days after lodging an Intent To Sell Form on the 25th of January. If the sale is conducted around the recent share price of US$0.50, it would amount to US$854k. Since March 2021, Steven's direct individual holding has decreased from 24.49m shares to 21.59m. Company insiders have collectively sold US$1.2m more than they bought, via options and on-market transactions in the last 12 months.
Seeking Alpha • Dec 07Tyme Technologies Offers Incredible Risk-RewardTyme Technologies recently reported their Q2 earnings that revealed the company only burned roughly $5M in cash with about $97M left in the bank. The small-cap sell-off has pushed the share price to fresh 52-week lows. I believe TYME has an incredible risk-reward at these prices. I review some of the company’s updates and point out a few bullish highlights for investors. In addition, I discuss some of my lingering downside risks for TYME. I update investors on my strategy for managing my TYME position and how I intend to take advantage of the sell-off.
분석 기사 • Nov 19Here's Why We're Not Too Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Recent Insider Transactions Derivative • Nov 01Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 1m shares in the next 90 days after lodging an Intent To Sell Form on the 26th of October. If the sale is conducted around the recent share price of US$0.97, it would amount to US$1.4m. Since December 2020, Steven's direct individual holding has decreased from 25.04m shares to 22.52m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Sep 25Independent Director recently bought US$52k worth of stockOn the 22nd of September, David Carberry bought around 50k shares on-market at roughly US$1.03 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold US$2.0m more in shares than they bought in the last 12 months.
Seeking Alpha • Aug 27Tyme Technologies: The Market Missed The Bullish MemoTyme Technologies recently made some big moves following a strategic review. I believe the market has missed the bullish memo about these changes. I review some of these significant changes and provide a bullish memo for investors. In addition, I discuss how these changes have addressed my downside concerns. The recent sell-off provided me with an opportunity to load up near the 52-week lows. I update investors on my strategy for managing my TYME position.
Recent Insider Transactions Derivative • Jul 29Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 1m shares in the next 90 days after lodging an Intent To Sell Form on the 20th of July. If the sale is conducted around the recent share price of US$1.05, it would amount to US$1.5m. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 23.84m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Jul 27Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 1m shares in the next 90 days after lodging an Intent To Sell Form on the 20th of July. If the sale is conducted around the recent share price of US$1.05, it would amount to US$1.5m. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 23.84m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Jul 24Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 1m shares in the next 90 days after lodging an Intent To Sell Form on the 20th of July. If the sale is conducted around the recent share price of US$1.05, it would amount to US$1.5m. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 23.84m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.
분석 기사 • Jul 19We're Not Very Worried About Tyme Technologies' (NASDAQ:TYME) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Recent Insider Transactions Derivative • May 03Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell 414k shares in the next 90 days after lodging an Intent To Sell Form on the 27th of April. If the sale is conducted around the recent share price of US$1.60, it would amount to US$662k. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 24.32m. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.
Price Target Changed • Apr 03Price target increased to US$9.44Up from US$8.50, the current price target is provided by 1 analyst. New target price is 405% above last closing price of US$1.87. Stock is up 87% over the past year.
Executive Departure • Apr 02Chief Medical Officer has left the companyOn the 31st of March, Giuseppe Del Priore's tenure in the role of Chief Medical Officer ended. We don't have any record of a personal shareholding under Giuseppe's name. A total of 2 executives have left over the last 12 months.
분석 기사 • Mar 26Here's Why We're Watching Tyme Technologies' (NASDAQ:TYME) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Recent Insider Transactions • Feb 21Insider recently sold US$55k worth of stockOn the 16th of February, Michael Demurjian sold around 20k shares on-market at roughly US$2.77 per share. In the last 3 months, there was an even bigger sale from another insider worth US$613k. Insiders have been net sellers, collectively disposing of US$1.8m more than they bought in the last 12 months.
분석 기사 • Feb 19Have Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Been Selling Their Stock?Investors may wish to note that an insider of Tyme Technologies, Inc. , Michael Demurjian, recently netted US$55k from...
Recent Insider Transactions • Feb 19Insider recently sold US$55k worth of stockOn the 16th of February, Michael Demurjian sold around 20k shares on-market at roughly US$2.77 per share. In the last 3 months, there was an even bigger sale from another insider worth US$613k. Insiders have been net sellers, collectively disposing of US$1.8m more than they bought in the last 12 months.
Is New 90 Day High Low • Feb 04New 90-day high: US$3.53The company is up 265% from its price of US$0.97 on 05 November 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 18% over the same period.
분석 기사 • Feb 02Do Institutions Own Tyme Technologies, Inc. (NASDAQ:TYME) Shares?A look at the shareholders of Tyme Technologies, Inc. ( NASDAQ:TYME ) can tell us which group is most powerful...
Recent Insider Transactions Derivative • Jan 24Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell roughly 519.00k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of January. If the sale is conducted around the recent share price of US$1.88, it would amount to US$976k. Since September 2020, Steven's direct individual holding has decreased from 26.01m shares to 24.93m. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months.
Is New 90 Day High Low • Jan 05New 90-day high: US$1.34The company is up 36% from its price of US$0.98 on 06 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Recent Insider Transactions • Dec 16Co-Founder recently sold US$613k worth of stockOn the 14th of December, Steven Hoffman sold around 500k shares on-market at roughly US$1.23 per share. This was the largest sale by an insider in the last 3 months. This was Steven's only on-market trade for the last 12 months.
Recent Insider Transactions Derivative • Dec 16Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell roughly 500.00k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of December. If the sale is conducted around the recent share price of US$1.26, it would amount to US$630k. Since December 2019, Steven's direct individual holding has decreased from 26.49m shares to 25.65m. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months.
분석 기사 • Dec 16Have Insiders Sold Tyme Technologies, Inc. (NASDAQ:TYME) Shares Recently?We wouldn't blame Tyme Technologies, Inc. ( NASDAQ:TYME ) shareholders if they were a little worried about the fact...
분석 기사 • Dec 09Is Tyme Technologies (NASDAQ:TYME) In A Good Position To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although...
Is New 90 Day High Low • Dec 01New 90-day high: US$1.05The company is up 7.0% from its price of US$0.99 on 01 September 2020. The American market is also up 7.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 27New 90-day low: US$0.92The company is down 23% from its price of US$1.20 on 29 July 2020. The American market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Recent Insider Transactions Derivative • Oct 24Co-Founder notifies of intention to sell stockSteven Hoffman intends to sell roughly 543.00k shares in the next 90 days after lodging an Intent To Sell Form on the 21st of October. If the sale is conducted around the recent share price of US$1.00, it would amount to US$543k. For the year to March 2020, Steven's total compensation was 61% salary and 39% non-salary. Since December 2019, Steven's direct individual holding has decreased from 26.49m shares to 25.95m. Company insiders have collectively sold US$1.1m more than they bought, via options and on-market transactions in the last 12 months.